Cancer treatments that genetically modify patients’ blood cells to target the disease have shown amazing results in clinical trials. Now drug companies and biotech’s must overcome big hurdles to get them into hospitals, including their potential cost. Daniel DeAngelo, associate professor of medicine at Dana-Farber Cancer Institute, is quoted.
